Idacio demonstrated similar efficacy to the reference product:
► Primary endpoint: PASI 75 response rate at Week 16 in moderate-to-severe psoriasis patients1
► Secondary endpoint: PASI 50/90/100 response rate at Week 16 in moderate-to-severe psoriasis patients1
    • Secondary endpoint: Similar PASI 50/75/90/100 response rates up to Week 521
Idacio demonstrated efficacy following switch from the reference product1

► Similar PASI 50/75/90/100 response rates at Week 52 in moderate-to-severe psoriasis patients1
► Similar ADA rates at Week 16 and up to Week 52 following switching in moderate-to-severe psoriasis patients†1,2

References:
1. Hercogová J et al. Br J Dermatol 2020; 182:316-326.
2. Clinical trials.gov. MSB11022 in moderate to severe chronic plaque psoriasis (AURIEL-PsO). Available at: https://clinicaltrials.gov/ct2/show/record/NCT02660580